Sionna Therapeutics (NASDAQ:SION) Releases Quarterly Earnings Results, Misses Expectations By $0.70 EPS

Sionna Therapeutics (NASDAQ:SION - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($3.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.68) by ($0.70), Zacks reports.

Sionna Therapeutics Stock Performance

SION traded down $1.59 on Monday, hitting $12.10. 252,963 shares of the stock traded hands, compared to its average volume of 239,104. Sionna Therapeutics has a 52 week low of $11.25 and a 52 week high of $25.19.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on SION shares. Guggenheim started coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They issued a "buy" rating and a $45.00 target price on the stock. TD Cowen began coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a "buy" rating for the company. Finally, Stifel Nicolaus initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They set a "buy" rating and a $32.00 target price on the stock.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.